ABRAHAM E. COHEN
Chairman of the Board of Directors
Abraham E. Cohen has been a director of NTI since March 1993 and has been chairman of the board since August 1993. From 1982 to 1992, Mr. Cohen served as Senior Vice President of Merck & Co. and from 1977 to 1988 as President of the Merck Sharp & Dohme International Division ("MSDI"). While at Merck, he played a key role in the development of Merck's international business, initially in Asia, then in Europe and, subsequently, as President of MSDI, which manufactures and markets human health products outside the United States. Since his retirement from Merck and MSDI in January 1992, Mr. Cohen has been active as an international business consultant. He was a director of Agouron Pharmaceuticals, Inc. until its merger with Warner-Lambert Company. He is currently Chairman and President of Kramex Corporation and serves as a director of four other public companies: Akzo Nobel N.V., Chugai Pharmaceutical Co., Teva Pharmaceutical Industries, Ltd. and Vasomedical, Inc.
THEODORE L. ELIOT, Jr.
Director
Theodore L. Eliot, Jr. has served as a director of NTI since August 1992. He joined the company in 1988 as Vice President. Mr. Eliot retired from the United States Department of State in 1978, after a 30-year career in which he held senior posts in Washington and was Ambassador to Afghanistan. He was Dean of the Fletcher School of Law and Diplomacy from 1978 to 1985 and a director of Raytheon Co. from 1983 to 1998. He is currently a director of Fiberstars, Inc. and of several non-profit organizations. Mr. Eliot holds B.A. and M.P.A. degrees from Harvard University.
WILLIAM A. FLETCHER
Director
William Fletcher is the Chairman of Teva – North America. Prior to that he was the President & CEO of Teva’s North American activities from 1985 until the end of 2004. Teva, one of Israel’s largest industrial companies, holds the leading position in the global generic drug industry and commands a significant presence in the specialty neurology market. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company’s acquisition by Teva and WR Grace. Prior to 1980, Mr. Fletcher was Business Development Manager and International Marketing Manager of Synthelabo, a pharmaceutical subsidiary of L’Oreal in Paris. From 1970 to 1977 he served in various international sales and marketing positions for Hoffman-LaRoche. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969. He serves as a Board Member for several Teva subsidiary companies in North America and Europe, and is a Director of Sportwall International Inc., a growth company in the interactive fitness industry.
PAUL E. FREIMAN
President and Chief Executive Officer
Paul E. Freiman joined NTI as a director and was subsequently appointed President and Chief Executive Officer. He is the former Chairman and Chief Executive Officer of Syntex Corporation, where he had a long and successful career and was instrumental in the sale of Syntex’s lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed by Proctor & Gamble as Aleve. Mr. Freiman currently serves as Chairman of the Board of Penwest Pharmaceuticals Co. He serves on the boards of Calypte Biomedical Corporation, NeoPharm Inc., NovaBay Pharmaceuticals, Otsuka America Pharmaceticals, Inc. and SciGen Ltd. He has also been chairman of the Pharmaceutical Manufacturers Association of Amercia (PhRMA) and has also chaired a number of key PhRMA committees. Mr. Freiman is also an advisor to Burrill & Company, a San Francisco merchant bank. Mr. Freiman holds a B.S. degree from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.
F. VAN KASPER
Director
F. Van Kasper joined the NTI board of directors in January 2004 and serves as chairman of the company's audit committee. Prior to his retirement in March 2003, Mr. Kasper served as Chairman of Wells Fargo Securities, the institutional brokerage and investment bank for Wells Fargo and Company. Mr. Kasper entered the brokerage business in 1964 with Merrill Lynch and in 1978 co-founded Van Kasper and Company, a regional investment bank. As Chairman and CEO of Van Kasper, he guided its growth from a handful of employees to one with over 350 employees in 15 offices in 4 states when the firm was sold in 1999. During his investment career, Mr. Kasper was elected as a Governor of the National Association of Securities Dealers (NASD) and as a Director and Vice Chairman of the Securities Industry Association (SIA). Mr. Kasper is active in the Bay Area non-profit community, most recently as Chairman of the Investment Committee for the University of California San Francisco Foundation (UCSF) and serves as Chairman Emeritus for San Francisco's Exploratorium Museum.
ABRAHAM D. SOFAER
Director
Has served as a director of the Company since April 1997. Mr. Sofaer is the first George P. Shultz Distinguished Scholar & Senior Fellow at the Hoover Institution, Stanford University, appointed in 1994. He has also been a Professor of Law (by courtesy) at Stanford Law School. From 1990 to 1994, Mr. Sofaer was a partner at the legal firm of Hughes, Hubbard & Reed in Washington, D.C., where he represented several U.S. public companies. From 1985 to 1990, he served as Legal Adviser to the United States Department of State, where he was principal negotiator on several international disputes. From 1979 to 1985, he served as a federal judge in the Southern District of New York. Mr. Sofaer is registered as a qualified arbitrator with the International Chamber of Commerce (ICC) Court of Arbitration, and the American Arbitration Association; he is also a member of the National Panel of the Center for Public Resolution of Disputes (CPR). He acts regularly as an arbitrator in merger-acquisition disputes, commercial cases involving valuation of technology and securities class action suits. Mr. Sofaer is on the board of directors of Gen-Probe, Inc., and Rambus, Inc. and serves on the International Advisory Committee of Chugai Biopharmaceuticals, Inc. He is president of American Friends of the Koret Israel Economic Development Fund and a director of the Koret Foundation, and is also Chairman of the National Museum of Jazz in Harlem. Mr. Sofaer holds a B.A. degree from Yeshiva College and a L.L.B. degree from New York University.
JOHN B. STUPPIN
Director
is a founder of the Company and has served as a director of the Company since September 1988. From September 1987 until October 1990, Mr. Stuppin served as President of the Company, from November 1990 to August 1993 as co-chairman of the Board, from October 1990 until September 1991 as Executive Vice President, and from April 1991 until July 1994 as Treasurer. He also served as acting Chief Financial Officer of the Company from the Company’s inception through December 1993. Mr. Stuppin is an investment banker and a venture capitalist. He has over 40 years experience in the start up and management of companies active in emerging technologies and has been the president of a manufacturing company. He is chairman of the board of Fiberstars, Inc. He has been a trustee of the San Francisco Conservatory of Music for over 30 years and has served as Governor of the Commonwealth Club of California and a trustee of the San Francisco Art Institute among other non-profit organizations. Mr. Stuppin holds an A.B. degree from Columbia University.
ENOCH CALLAWAY, M.D.
Board Member Emeritus
Is a founder of the Company and served as a director of the Company from September 1987 to February 2008. Dr. Callaway previously served as chairman of the Board of the Company from September 1987 to November 1990, as co-chairman of the Board of the Company from November 1990 until August 1993, as Vice President of the Company from September 1988 until August 1993 and as Secretary of the Company from September 1988 until September 1991. Dr. Callaway has been Emeritus Professor of Psychiatry at the University of California, San Francisco since 1986, where he also served as Director of Research at the Langley Porter Psychiatric Institute from 1959 to 1986. Dr. Callaway was Staff Psychiatrist, SFVAMC, 1996-1997. He is a member of the Institutional Review Board for SAM Technologies, Inc and Abratech, Inc. He continues to practice clinical psychopharmacology part time.
|
